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OBJECTIVES We undertook an analysis of weight cycling, coronary risk factors and angiographic coronary
artery disease (CAD) in women.
BACKGROUND The effect of weight cycling on cardiovascular mortality and morbidity is controversial, and
the impact of weight cycling on cardiovascular risk factors is unclear.
METHODS This is a cross-sectional population study of 485 women with coronary risk factors
undergoing coronary angiography for evaluation of suspected myocardial ischemia enrolled in
the Women’s Ischemia Syndrome Evaluation (WISE). Reported lifetime weight cycling—
defined as voluntary weight loss of at least 10 lbs at least 3 times—coronary risk factors
including core laboratory determined blood lipoproteins and CAD, as determined by a core
angiographic laboratory, are the main outcome measures.
RESULTS Overall, 27% of women reported weight cycling—19% cycled 10 to 19 lbs, 6% cycled 20 to
49 lbs, and 2% cycled 501 lbs. Reported weight cycling was associated with 7% lower
high-density lipoprotein cholesterol (HDL-C) levels in women (p 5 0.01). The HDL-C
effect was directly related to the amount of weight cycled with women who lost $50 lbs/cycle
having HDL-C levels 27% lower than noncyclers (p 5 0.0025). This finding was
independent of other HDL-C modulators, including estrogen status, physical activity level,
alcohol intake, body mass index, diabetes, beta-blocker use, cigarette smoking and race.
Weight cycling was not associated with an increased prevalence of CAD in this population.
CONCLUSIONS Weight cycling is associated with lower HDL-C in women of a magnitude that is known to
be associated with an increased risk of cardiac events as demonstrated in prior clinical trials.
(J Am Coll Cardiol 2000;36:1565–71) © 2000 by the American College of Cardiology
The effect of weight cycling (repeated weight loss and
weight gain) on cardiovascular mortality and morbidity is
controversial. Previous studies have shown that while
weight loss has a beneficial effect on cardiovascular risk
factors in obese patients, especially those with comorbidities
(1,2), weight cycling may confer an elevated risk of death
from cardiovascular disease (3–6). In 1994, the National
Task Force on the Prevention and Treatment of Obesity
concluded, “Although conclusive data on the long-term
effects of weight cycling are lacking, non-obese individuals
should attempt to maintain a stable weight” (7). Given that
40% of adult women report attempts to lose weight (8),
there is a compelling need for investigation in this area.
Investigation into biologically plausible mechanisms,
whereby weight cycling might elevate cardiovascular risk, is
limited. Studies evaluating weight loss and regain in animals
have been inconsistent (9). Previous studies performed on
obese/overweight women and men have failed to demon-
strate any adverse relationships between weight cycling and
coronary risk factors (10,11). Finally, much of the previous
work has not distinguished intentional from unintentional
weight loss (7).
We undertook an analysis of weight cycling, coronary risk
factors and angiographic coronary artery disease (CAD) in
women enrolled in the Women’s Ischemia Syndrome Eval-
uation (WISE). We hypothesized that weight cycling would
be associated with an adverse effect on coronary risk factors,
thereby potentially promoting the development of CAD.
METHODS
The WISE study is a National Heart, Lung and Blood
Institute (NHLBI) sponsored four-center study that aims to
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improve the diagnostic reliability of cardiovascular testing in
the evaluation of ischemic heart disease in women. Each
center obtained appropriate institutional review board ap-
proval and participant consent before the initiation of
testing. Women with chest pain symptoms or suspected
ischemia undergo an initial evaluation that includes the
collection of demographic, medical history, psychosocial
and symptom data as well as blood sampling. Subjects also
undergo a physical examination that includes height, weight
and waist-hip ratio determination, followed by quantitative
coronary angiography. Body mass index (BMI) was calcu-
lated by dividing weight in kilograms by the square of height
in meters; a BMI of .30 was defined as obese (12).
Determination of waist-hip ratio involved measurement of
the waist at the natural waistline and the hip at the widest
part, across the buttocks. Blood pressure was measured
twice using a standard protocol. An average of the two
measurements was used for data analysis. The complete
study design and methodology of the WISE study are
described elsewhere (13).
Definition of weight cycling. During the baseline evalua-
tion each woman was asked about the number of times in
her life that she had intentionally lost a specified number of
lbs through dieting, exercise, a formal weight control
program or on her own. Pregnancy and childbirth were not
included. Ranges of weight were indicated rather than
actual weight loss. Women were asked to select from five
weight-loss ranges, beginning with 10 to 19 lbs and ending
with 100 or more lbs. The number of times that the women
had lost the weight ranged from never to more than 10
times. For the purpose of these analyses, weight cycling was
defined a priori as weight loss of at least 10 lbs at least 3
times.
Lipoprotein analyses. Lipoprotein determinations were
performed at a lipid core laboratory enrolled in the Centers
for Disease Control and prevention lipid standardization
program previously used in multiple NHLBI-sponsored
lipid-lowering intervention trials. Total plasma cholesterol
(TC), triglycerides and high-density lipoprotein cholesterol
(HDL-C) were determined by enzymatic assay, and low-
density lipoprotein cholesterol was calculated using the
Friedewald formula, as previously published (14). The
coefficients of variation for TC, HDL-C and triglycerides
were 1.80%, 1.23% and 3.93%, respectively.
Measures of physical activity and functional capacity. A
version of the Postmenopausal Estrogen/Progesterone In-
tervention Activity Questionnaire (PEPI-Q) (15) was used
to assess physical activity. The PEPI-Q is a brief question-
naire that covers three areas of physical activity: activity at
work, home and during leisure time. The total PEPI-Q
score was calculated, and then the score was weighted to
account for “Not Applicable” responses for women not
employed outside the home. The weighting involved sub-
stituting the average value on completed questions for this
item. The scores ranged from 1.5 to 12, with a higher score
indicating greater activity. The Duke Activity Status Index
(16) was used to assess functional capacity. This 12-item
scale measures the ability to perform common daily activi-
ties. Again, a higher score is indicative of greater functional
capacity.
Risk factors. The risk factors examined were from the
National Cholesterol Education Program Adult Treatment
Panel II (17) and included age 55 years or older or
menopause without current hormone replacement therapy
(HRT), positive family history for CAD (CAD in male first
degree relative ,55 years old or a female first degree relative
,65 years old), current cigarette smoking, hypertension
(history of hypertension or blood pressure .140 mm Hg
systolic or .90 mm Hg diastolic), HDL-C ,35 mg/dl and
a history of diabetes mellitus.
Measurement of quantitative angiography. Coronary an-
giograms were analyzed by a core laboratory used in previ-
ous multicenter trials with angiographic outcomes. Mea-
surements included quantitative assessment as to the
presence, severity and complexity of epicardial coronary
artery stenoses, using previously published methods (18).
Statistical analysis. Comparisons between reported weight
cyclers and noncyclers were performed by the Wilcoxon
rank-sum test for continuous measures and by the chi-
square test for discrete measures. Probability values of
#0.05 were considered statistically significant. The rela-
tionship between obesity (BMI . 30) and reported weight
cycling with HDL-C levels was assessed using a general
linear model. This kind of modeling was also used in
examining the relationship between amount of weight lost
during each cycle and HDL-C. Stepwise regression analysis
was used to model HDL-C as a function of weight cycling
and other coronary risk factors including race, age, BMI,
waist-hip ratio, physical activity, functional capacity, diabe-
tes, menopausal status, current HRT, alcohol and beta-
blocker agent use. These variables were chosen for entry into
the model based upon univariate and multivariate associa-
tions as well as literature review of relevant, confounding
variables. Criteria for entry into the model was p 5 0.15.
Analyses were performed using SAS software release 6.12.
RESULTS
Reported weight cycling by participant characteristics is
shown in Table 1. One hundred thirty (27%) women
Abbreviations and Acronyms
BMI 5 body mass index
CAD 5 coronary artery disease
HDL-C 5 high-density lipoprotein cholesterol
HRT 5 hormone replacement therapy
NHLBI 5 National Heart, Lung and Blood Institute
PEPI-Q 5 Postmenopausal Estrogen/Progesterone
Intervention Activity Questionnaire
TC 5 total plasma cholesterol
WISE 5 Women’s Ischemia Syndrome Evaluation
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reported a history of weight cycling; 19% cycled 10 to 19 lbs,
6% cycled 20 to 49 lbs, and 2% cycled 501 lbs. Overall, 426
(88%) of the women had at least one National Cholesterol
Education Program Adult Treatment Panel II risk factor,
and 334 (69%) had multiple (two or more) risk factors.
Women who reported weight cycling were younger (Ta-
ble 2), more often white and better educated compared with
noncyclers (Table 1). However, there was no difference
between reported cyclers and noncyclers in menopausal
status, the proportion currently using HRT, diabetes or the
prevalence of CAD (Table 1).
Comparison of coronary risk factors and angiographic
CAD among women reporting weight cycling compared
with those reporting no weight cycling is shown in Table 2.
Notably, women reporting weight cycling had significantly
lower HDL-C levels (7%) (p 5 0.01) and higher (8%)
TC/HDL-C (p 5 0.03) than noncyclers. They also had a
higher BMI at study entry, higher levels of physical activity
and higher functional capacity. There was no difference
between cyclers and noncyclers for the usual cardiac risk
factors such as blood pressure, fasting blood sugar or
waist-hip ratio.
Table 1. Reported Weight Cycling by Participant Characteristics
Weight
Cycle
Do Not
Weight Cycle
Characteristic n % % p Value
Race
White 395 30 70 0.003
Other 90 14 86
Education
,High school 101 19 81 0.04
High school 208 27 73
.High school 175 31 69
BMIp.30 191 37 63 0.001
BMI #30 290 20 80
Postmenopausal
Yes 366 26 74 0.67
No 117 28 72
HRT currently (postmenopausal)
Yes 152 28 72 0.75
No 203 26 74
Diabetes†
Yes 93 30 70 0.42
No 392 26 74
CAD ($50% $1 coronary artery)
Yes 186 24 76 0.34
No 244 28 72
*Body mass index calculated as described in Methods; †history of diabetes treated with insulin and/or oral medication.
BMI 5 body mass index; CAD 5 coronary artery disease; HRT 5 hormone replacement therapy; n 5 number of women;
% 5 % in category.
Table 2. Coronary Risk Factors by Reported Weight Cycling
Risk Factor n
Weight
Cycle
(n 5 130) n
No Weight
Cycle
(n 5 355) p Value
Age (yrs) (6SD) 130 55.8 6 10.8 355 59.7 6 11.8 0.001
Systolic blood pressure (mm Hg) (6SD) 130 134 6 18 355 138 6 22 0.16
Diastolic blood pressure (mm Hg) (6SD) 130 77 6 11 355 76 6 11 0.30
Fasting Blood Sugar (mg/dl) (6SD) 76 126 6 64 231 118 6 58 0.27
TC (mg/dl) (6SD) 124 201 6 44 342 203 6 46 0.75
Triglycerides (mg/dl) (6SD) 122 163 6 153 341 159 6 97 0.78
HDL-C (mg/dl) (6SD) 120 52 6 12 338 56 6 14 0.01
LDL-C (mg/dl) (6SD) 118 120 6 42 336 115 6 40 0.28
TC/HDL-C (6SD) 120 4.1 6 1.4 338 3.8 6 1.1 0.03
Weight (lbs) (6SD) 130 182 6 35 351 163 6 36 0.0001
BMI* (6SD) 130 32 6 7 351 29 6 6 0.0001
Waist-hip ratio (6SD) 112 0.87 6 0.11 351 0.87 6 0.11 0.57
Alcohol intake (drinks/week) (6SD) 129 0.60 6 3.3 355 0.67 6 3.9 0.32
Physical activity (6SD) 130 7.7 6 1.7 355 7.1 6 2.0 0.0008
Functional capacity (6SD) 130 20.7 6 12.8 355 18.1 6 13.2 0.02
*BMI 5 body mass index calculated as described in Methods.
HDL-C 5 high-density lipoprotein cholesterol; lbs 5 pounds; LDL-C 5 low-density lipoprotein cholesterol; SD 5 standard deviation; TC 5 total cholesterol.
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Next, we evaluated whether reported weight cycling
independently contributed to the lower observed HDL-C
levels. Weight cycling was shown to be an independent,
significant predictor of HDL-C (Table 3), taking into
account age, race, BMI, current smoking, current HRT use,
diabetes, waist-hip ratio, alcohol consumption, physical
activity, functional capacity, menopausal status and use of
beta-blockers. When we controlled for known modulators
of HDL-C, such as BMI, current HRT and cigarette
smoking, the same predictors were found with similar p
values.
Since elevated BMI was one of the strongest and most
prevalent determinants of reduced HDL-C, we stratified
women into four groups according to the presence or
absence of obesity (BMI . 30) and weight cycling (Table
4). Both weight cycling and obesity were significant factors
in the model. The mean BMI of the obese women (both
cyclers and noncyclers) was 36, while the non-obese had a
mean BMI of 27 (cyclers) and of 25 (noncyclers). Women
who were both obese and reported weight cycling had the
lowest HDL-C levels, while women with neither charac-
teristic had the highest (p 5 0.001).
We examined different thresholds of weight cycling to
ascertain if there is a “dose-effect” relationship between
reported weight cycling and lower HDL-C. Similar mag-
nitudes of lower HDL-C were observed in the groups of
women who reported weight cycling at different thresholds,
greater or equal to 3, 6 or 10 times compared with those
with fewer than 3, 6 or 10 cycles, respectively. With the
threshold of $10 times (n 5 41), there was a trend toward
a lower HDL-C compared with those who cycled ,10
times: 51.6 mg/dl 6 11.7 versus 55.0 mg/dl 6 13.6,
respectively (p 5 0.14). We also looked at women who
reported cycling 3 or more times and lost 10 to 19 lbs, 20 to
49 lbs or $50 lbs with each cycle. Lower HDL-C levels
were observed with increasing amounts of weight cycled
(Fig. 1). There was a trend to increasing BMI with each
category of weight loss, and adjustment of the HDL-C
levels for BMI did not substantially affect the relationship.
Repeat analysis of all the demographic, risk factor and
coronary angiographic variables using a lower threshold for
obesity (BMI . 27) demonstrated similar results.
DISCUSSION
Effect of weight cycling. This study’s findings demonstrate
that reported weight cycling is associated with lower
HDL-C levels in women with multiple risk factors being
evaluated for suspected myocardial ischemia. Our findings
of 3 mg/dl to 5 mg/dl lower HDL-C levels in women with
reported weight cycling as compared with noncyclers and as
much as a 15 mg/dl lower value for women reporting large
($50 lbs) weight cycles could have widespread clinical
significance. The 7% difference in HDL-C between cyclers
and noncyclers is of a similar magnitude as that recently
shown in men to impact major coronary events in the
Veterans Affairs Cooperative Studies Program High-
Density Lipoprotein Cholesterol Intervention Trial (19).
After 5 years of follow-up a 6% increase in HDL-C levels
using gemfibrozil resulted in a 22% reduction in major
coronary events. Similar results were found in the earlier
Helsinki Heart Study (20).
The adverse effect of weight cycling on HDL-C levels
appears to be independent from other known modulators of
HDL-C, specifically BMI, (21,22) abdominal adiposity,
cigarette smoking, physical activity level, alcohol intake,
HRT (23), diabetes (24) and race. The biologic plausibility
of these findings is further supported by a “dose-response”
effect showing that the greater magnitudes of reported
weight cycled are associated with significantly lower
HDL-C levels.
Coronary risk factors. These results document an associ-
ation between a measure of weight cycling and a significant
coronary risk factor, HDL-C. While controversy still exists
regarding how best to define weight cycling, large epidemi-
ologic studies using a variety of measures (3–6,25) have
predominantly indicated an adverse effect for all-cause and
cardiovascular mortality. Notably, we did not find a signif-
icant association between reported weight cycling and an-
giographic CAD, suggesting that the potential link between
weight cycling and cardiovascular mortality may be non-
atherogenic. Alternatively, there may be a lag time between
decreases in HDL-C and their effect on the development of
CAD since our weight cyclers were younger compared with
noncyclers. We are unable to evaluate this with our current
data. The relatively low prevalence of significant CAD in
Table 3. Significant Independent Predictors of HDL-C (mg/dl)
(Linear Regression Model)
Variable
Parameter Estimate
(6 SE)† p Value
Weight cycling (yes vs. no) 23.43 (6 1.51) 0.02
BMI 20.38 (6 0.11) 0.0001
Current smoker (yes vs. no) 26.49 (6 1.66) 0.0001
Current HRT (yes vs. no) 3.61 (6 1.33) 0.001
Diabetes* (yes vs. no) 24.39 (6 1.75) 0.008
Waist-hip ratio 213.75 (6 6.15) 0.02
Intercept 82.45 (6 6.03) —
*History of diabetes treated with insulin and/or oral medications; †SE 5 standard
error. Race, age, activity, alcohol consumption, functional capacity and use of
beta-blockers were considered but were not significant independent explanatory
variables.
BMI 5 body mass index; HDL-C 5 high-density lipoprotein cholesterol;
HRT 5 hormone replacement therapy; SE 5 standard error.
Table 4. HDL-C Levels (mg/dl) by Presence or Absence of
Obesity/Weight Cycling*
Obese
(BMI >30)
Weight Cycling
Yes No
Yes (n 5 65) (n 5 116)
49.7 (6 12.2) mg/dl 53.6 (6 11.3) mg/dl
No (n 5 55) (n 5 218)
54.1 (6 11.1) mg/dl 56.9 (6 14.9) mg/dl
*p 5 0.001, both weight cycling and obesity were significant factors in the model.
BMI 5 body mass index; HDL-C 5 high-density lipoprotein cholesterol.
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our women may also have limited our ability to detect a
relationship between weight cycling and CAD. Previous
work analyzing various measures of weight cycling and
coronary risk factors has been mainly negative for significant
associations (10,11). Human studies have predominantly
studied obese, but otherwise healthy, subjects attempting
weight loss and not high risk women with multiple coronary
risk factors undergoing evaluation of suspected CAD, as in
this study population.
Current study procedures. The current study data collec-
tion and quantitation procedures represent an improvement
compared with prior related study methods. Women’s
Ischemia Syndrome Evaluation used study coordinator-
directed historical questionnaire data collection, rather than
mail-in self-report, and women were asked specifically
about intentional weight loss. Lipoprotein determinations
were performed in batch analyses by a Centers for Disease
Control standardized core lab, with known excellent coef-
ficients of variation. We also measured potentially con-
founding variables not assessed previously in weight cycling
studies, such as waist-hip ratio, physical activity, alcohol
intake, menopausal status and hormone replacement use.
Not measuring and adjusting for these variables may have
confounded a relationship of HDL-C and weight cycling in
earlier studies. For example, our women reporting weight
cycling were significantly more physically active compared
with non-weight cyclers, which, as a beneficial moderating
variable of HDL-C, may have masked an adverse HDL-C
effect in prior studies.
Mechanisms. Possible biologic mechanisms linking weight
cycling and lower HDL-C levels in women are speculative.
Intentional weight loss typically results from caloric depri-
vation, shifting basal metabolism to a state of energy
conservation and catabolism of endogenous energy stores
(26). Metabolic studies have demonstrated that short-term
hypocaloric weight loss without change in physical activity
results in a minor HDL-C decrease (0.27 mg/dl), which
shifts to an increase during weight stabilization (0.35 mg/dl)
(27). This change appears to be driven by the sympathetic
nervous system-mediated insulin and thyroid hormone level
reductions, which conserve energy by reducing thermogen-
esis (26). Weight cycling may reduce HDL-C levels by
contributing to the dysmetabolic syndrome of insulin resis-
tance/impaired glucose tolerance, abdominal adiposity and
hypertension associated with CAD (28). This concept is
consistent with our findings that weight cycling is an
independent predictor of HDL-C, even after adjustment for
diabetes in the multivariate model. The ultimate metabolic
pathways responsible for determining a net HDL-C effect
of repeated weight loss and weight gain are likely complex
and individually mediated. Further work is needed to
evaluate the possible metabolic pathways linking weight
cycling and HDL-C.
Study limitations. The current study results are limited by
the cross-sectional design, which precludes inference re-
garding causality between reported weight cycling and
HDL-C. Additionally, we are unable to control for unmea-
sured variables or draw conclusions regarding a pathophys-
iological sequence of associations. We did not collect
Figure 1. Box plots of HDL-C levels (mg/dl) by magnitude of weight cycled at least 3 times. Extreme values are at the ends; quartile values are on the
corners of the box. p 5 0.0025 (general linear model). HDL-C 5 high-density lipoprotein cholesterol.
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information on how recently the last weight cycling occurred or
about the use of diet pills/sympathetic nervous system stimu-
lants as aids to weight loss. Use of self-reported weight cycling
can also be viewed as a limitation compared with actual body
weight measurement over time. However, there are drawbacks
to these methods as well (29). The relevance of our HDL-C
findings is reduced by the lack of concurrent adverse coronary
angiographic findings. The WISE enrollment is continuing,
and these relationships will be examined in the larger popula-
tion at the end of the study. Alternatively, the lack of
concordance with coronary angiography may suggest that
HDL-C is a marker of nonatherogenic sympathetic nervous
system changes triggered by weight cycling that could increase
cardiovascular mortality.
Our study consists of women with chest pain symptoms
suspected to be ischemic and referred for coronary angiog-
raphy; biases inherent in this population (30) may also limit
generalizability.
Relevance. Low HDL-C is a particularly potent risk factor
for cardiovascular mortality in women. Follow-up of Fra-
mingham women showed a clear inverse association be-
tween HDL-C and myocardial infarction (31). Evidence
from the largest epidemiological studies suggests that, for
each 1 mg/dl increase in HDL-C, a 3% decease in coronary
heart disease risk in women may occur (32). The recent
American Heart Association/American College of Cardiol-
ogy guide to preventive cardiology in women (33) makes
several recommendations for focused risk factor manage-
ment in women, including more aggressive targets for
HDL-C and triglycerides.
Since this study found a relationship between HDL-C
levels and reported weight cycling that is independent of
BMI, these results may be relevant to all women who weight
cycle, including non-obese women. We conclude with the
1994 recommendation of the National Task Force on the
Prevention and Treatment of Obesity, “Although conclu-
sive data on the long-term effects of weight cycling are
lacking, non-obese individuals should attempt to maintain a
stable weight” (7).
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